Stock Analysis
argenx Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
argenx (EBR:ARGX) Full Year 2023 Results
Key Financial Results
- Revenue: US$1.27b (up 188% from FY 2022).
- Net loss: US$295.1m (loss narrowed by 58% from FY 2022).
- US$5.16 loss per share (improved from US$13.05 loss in FY 2022).
ARGX Products In Clinical Trials
- Phase I: 2.
ARGX Post-Clinical Trial Products
- Pre-registration: 3.
All figures shown in the chart above are for the trailing 12 month (TTM) period
argenx Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 5.4%. Earnings per share (EPS) missed analyst estimates by 11%.
In the last 12 months, the only revenue segment was Biotechnology contributing US$1.27b. Notably, cost of sales worth US$977.3m amounted to 77% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$711.9m (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$125.6m. Explore how ARGX's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.
Performance of the market in Belgium.
The company's shares are up 8.0% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with argenx, and understanding them should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether argenx is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTBR:ARGX
argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
High growth potential with excellent balance sheet.